View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 7, 2022

Eucure doses first patient with triple antibody combo in Phase I solid tumour trial

The trial will analyse the safety, tolerability and efficacy of YH003, YH001 and pembrolizumab in solid tumour patients.

Eucure Biopharma, a Biocytogen subsidiary, has dosed the first subject in Phase I clinical trial of its YH003 along with YH001 and pembrolizumab to treat advanced solid tumour patients in Australia.

YH003 is a humanised IgG2 anti-CD40 monoclonal antibody (mAb), while YH001 and pembrolizumab are anti-CTLA-4 and anti-PD-1 mAbs, respectively.

The open-label, dose-escalation trial will analyse the safety, tolerability and efficacy of the triple mAb combination of YH003, YH001 and pembrolizumab in advanced solid tumour patients. 

Furthermore, the trial will assess YH003’s pharmacokinetics and immunogenicity.

YH003 was found to offer robust anti-tumour effects against multiple tumour models, when used as a monotherapy or along with anti-PD-1 mAb drugs, in Biocytogen’s humanised CD40 mice, without showing hepatotoxicity or other toxicities. 

In addition, YH003 substantially boosted the infiltration of anti-tumour T cells into tumours, pharmacodynamic studies in mice showed.

Eucure Biopharma chairman and CEO Dr Yuelei Shen said: “Previous Phase I clinical trials of YH003/Toripalimab (anti-PD-1 mAb) combination therapy and YH001/Toripalimab combination therapy indicate desirable safety profiles and preliminary efficacy for both products. 

“The combination of CTLA-4, PD-1 and CD40 mAbs is based on their different but complementary biological mechanisms; we hope that the three-drug combination study can further strengthen the antitumour efficacy to benefit patients.”

In March last year, the company dosed the first subject in a multi-regional Phase I trial of YH002 plus YH001 in Australia. 

Eucure intends to carry out this open-label, dose-escalation trial in Australia and China to assess the safety, tolerability and initial efficacy of YH002 plus YH001 in advanced solid tumour patients.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy